Exploring Epigenetic Modifications as Potential Biomarkers and Therapeutic Targets in Glaucoma

Area of Science:

• Ophthalmology and Genetics
• Neuroscience
• Molecular Biology

Background:

• Glaucoma is a leading cause of irreversible blindness, characterized by neurodegeneration of the optic nerve.
• Current glaucoma management faces challenges in early diagnosis and effective treatment.
• Epigenetic modifications (DNA methylation, histone modifications, non-coding RNAs) regulate gene expression and cellular processes.

Purpose of the Study:

• To provide a comprehensive review of epigenetics in glaucoma.
• To elucidate the role of epigenetic modifications in glaucoma pathogenesis and neurodegeneration.
• To discuss the potential of epigenetic biomarkers and therapeutic targets for personalized glaucoma treatment.

Main Methods:

• Review of existing literature on glaucoma pathophysiology and epigenetics.
• Analysis of evidence from animal models and human studies on epigenetic alterations in glaucoma.
• Synthesis of current understanding of epigenetic mechanisms in glaucoma onset and progression.

Main Results:

• Epigenetic modifications, including DNA methylation and histone modifications, significantly influence gene expression relevant to glaucoma.
• These epigenetic alterations are implicated in the neurodegenerative processes underlying glaucoma.
• Evidence suggests a link between specific epigenetic changes and glaucoma development and progression.

Conclusions:

• Epigenetics plays a critical role in the complex pathogenesis of glaucoma.
• Epigenetic modifications offer potential as diagnostic biomarkers for early glaucoma detection.
• Targeting epigenetic mechanisms presents a promising avenue for novel, personalized glaucoma therapies.